RU2006122853A - Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы - Google Patents
Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы Download PDFInfo
- Publication number
- RU2006122853A RU2006122853A RU2006122853/04A RU2006122853A RU2006122853A RU 2006122853 A RU2006122853 A RU 2006122853A RU 2006122853/04 A RU2006122853/04 A RU 2006122853/04A RU 2006122853 A RU2006122853 A RU 2006122853A RU 2006122853 A RU2006122853 A RU 2006122853A
- Authority
- RU
- Russia
- Prior art keywords
- dependent
- disease
- group
- treatment
- pharmaceutically acceptable
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 13
- 102000001253 Protein Kinase Human genes 0.000 title claims 7
- 108060006633 protein kinase Proteins 0.000 title claims 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 230000001419 dependent effect Effects 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- OBHVFBJZHBSDOF-UHFFFAOYSA-N 1-phenyl-3-(4-pyrimidin-4-yloxyphenyl)urea Chemical compound C=1C=C(OC=2N=CN=CC=2)C=CC=1NC(=O)NC1=CC=CC=C1 OBHVFBJZHBSDOF-UHFFFAOYSA-N 0.000 claims 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N Z-phenylurea Natural products NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- -1 pyrimidin-4-yloxy Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Применение соединения формулы I
где G означает отсутствующий радикал, (низш.)алкилен или С3-С5циклоалкилен, a Z означает радикал формулы Ia
или G означает отсутствующий радикал, а Z означает радикал формулы Ib
А означает СН, N или N→O, а А' означает N или N→O, при условии, что не более чем один из А и А' может означать N→O,
n равно 1 или 2,
m равно 0, 1 или 2,
р равно 0, 2 или 3,
r равно 0-5,
Х означает NR, если р равно 0, где R означает водород или органическую фрагмент, или, если р равно 2 или 3, Х означает азот, который вместе с группой (СН2)р и химическими связями, указанными пунктирными (прерывистыми) линиями (включая атомы, к которым они присоединены), образуют цикл, или
Х означает СНК, где К означает (низш.)алкил или водород, а р равно нулю, при условии, что химические связи, указанные пунктирными линиями отсутствуют, если р равно нулю,
Y1 означает О, S или СН2,
Y2 означает О, S или NH,
при условии, что (Y1)n-(Y2)m не включает группы O-O, S-S, NH-O, NH-S или S-O,
каждый R1, R2, R3 и R5 независимо друг от друга означает водород, или неорганический или органический фрагмент или любые два из них образуют мостиковую группу (низш.)алкилендиокси, связанную через атомы кислорода, а оставшийся один из этих фрагментов означает водород или неорганический или органический фрагмент,
и R4 (присутствующий, если r не равно нулю) означает неорганический или органический фрагмент,
или его таутомера или фармацевтически приемлемой соли для получения фармацевтической композиции, предназначенной для лечения RET-зависимых заболеваний.
2. Применение по п.1, где RET-зависимое заболевание означает RET-зависимое опухолевое заболевание.
3. Применение по п.2, где RET-зависимое опухолевое заболевание выбирают из рака толстой кишки, рака легких, рака молочной железы, рака поджелудочной железы и рака щитовидной железы.
4. Применение по п.3, где рак означает рак щитовидной железы.
5. Производное N-[4-(пиримидин-4-илокси)фенил]-N'-фенилмочевины, выбранное из группы, включающей соединения, описанные в примерах 1-67, 68-70 или 71-95, или его соль.
6. Фармацевтическая композиция, включающая производное N-[4-(пиримидин-4-илокси)фенил]-N'-фенилмочевины, выбранное из группы, включающей соединения, описанные в примерах 1-67, 68-70 или 71-95, или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
7. Производное N-[4-(пиримидин-4-илокси)фенил]-N'-фенилмочевины, выбранное из группы, включающей соединения, описанные в примерах 1-67, 68-70 или 71-95, или его фармацевтически приемлемая соль, для применения при лечении животного или человека, особенно для лечения зависимого от протеинкиназы заболевания.
8. Соединение по п.7, где зависимое от протеинкиназы заболевание, подлежащее лечению, означает заболевание, зависимое от протеинтирозинкиназы, особенно пролиферативное заболевание, зависимое от любой одной или более следующих протеинтирозинкиназ: с-Abl, Bcr-Abl, Flt-3, RET, VEGF-R и/или Tek, особенно Flt-3.
9. Применение производного N-[4-(пиримидин-4-илокси)фенил]-N'-фенилмочевины, выбранного из группы, включающей соединения, описанные в примерах 1-67, 68-70 или 71-95, или его фармацевтически приемлемой соли, для использования при лечении зависимого от протеинкиназы заболевания.
10. Применение производного N-[4-(пиримидин-4-илокси)фенил]-N'-фенилмочевины, выбранного из группы, включающей соединения, описанные в примерах 1-67, 68-70 или 71-95, или его фармацевтически приемлемой соли, для приготовления фармацевтической композиции, предназначенной для использования при лечении зависимого от протеинкиназы заболевания.
11. Применение по п.9 или 10, где зависимое от протеинкиназы заболевание означает заболевание, зависимое от протеинтирозинкиназы, особенно пролиферативное заболевание, зависимое от любой одной или более следующих протеинтирозинкиназ: с-Abl, Bcr-Abl, Flt-3, RET, VEGF-R и/или Tek, особенно Flt-3.
12. Способ лечения заболевания, чувствительного к ингибированию протеинкиназы (особенно тирозинпротеинкиназы), включающий введение теплокровному животному, например человеку, которому необходимо такое лечение, профилактически или предпочтительно терапевтически эффективного количества производного N-[4-(пиримидин-4-илокси)фенил]-N'-фенилмочевины, выбранного из группы, включающей соединения, описанные в примерах 1-67, 68-70 или 71-95, или его фармацевтически приемлемой соли.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0327734A GB0327734D0 (en) | 2003-11-28 | 2003-11-28 | Organic compounds |
| GB0327734.0 | 2003-11-28 | ||
| GB0417805A GB0417805D0 (en) | 2004-08-10 | 2004-08-10 | Organic compounds |
| GB0417805.9 | 2004-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006122853A true RU2006122853A (ru) | 2008-01-10 |
Family
ID=34635447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006122853/04A RU2006122853A (ru) | 2003-11-28 | 2004-11-26 | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080312192A1 (ru) |
| EP (1) | EP1689376A2 (ru) |
| JP (1) | JP2007515400A (ru) |
| KR (1) | KR20060110307A (ru) |
| AR (1) | AR047496A1 (ru) |
| AU (2) | AU2004292773A1 (ru) |
| BR (1) | BRPI0416935A (ru) |
| CA (1) | CA2546673A1 (ru) |
| PE (1) | PE20051046A1 (ru) |
| RU (1) | RU2006122853A (ru) |
| TW (1) | TW200529849A (ru) |
| WO (1) | WO2005051366A2 (ru) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308310C (zh) | 2000-10-20 | 2007-04-04 | 卫材R&D管理有限公司 | 含氮芳环衍生物 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
| US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| HRP20130602T1 (en) | 2003-07-30 | 2013-07-31 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
| DK1765327T3 (da) | 2004-06-17 | 2014-11-03 | Cytokinetics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| AU2011253934C1 (en) * | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
| CN101115761B (zh) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物的前药及其应用 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| JP5301284B2 (ja) | 2005-12-15 | 2013-09-25 | サイトキネティクス・インコーポレーテッド | 特定の化学物質、組成物および方法 |
| EP1962852B1 (en) | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| KR101406956B1 (ko) | 2005-12-21 | 2014-06-13 | 노파르티스 아게 | Ｆｇｆ 억제제로서의 피리미디닐 아릴 우레아 유도체 |
| PT1973545E (pt) | 2005-12-23 | 2013-02-11 | Ariad Pharma Inc | Compostos de heteroarilo bicíclicos |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| EP1991532B1 (en) | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| CA2651822A1 (en) | 2006-05-08 | 2007-11-22 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
| JP5190361B2 (ja) | 2006-05-18 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 甲状腺癌に対する抗腫瘍剤 |
| WO2008021288A2 (en) * | 2006-08-11 | 2008-02-21 | Johns Hopkins University | Consensus coding sequences of human breast and colorectal cancers |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| AU2013231117B2 (en) * | 2006-12-14 | 2016-06-02 | Janssen Pharmaceutica N.V. | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives |
| BRPI0720741A2 (pt) * | 2006-12-22 | 2014-01-28 | Hoffmann La Roche | Derivados de primidila como inibidores da proteína cinase. |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| GB0706932D0 (en) * | 2007-04-10 | 2007-05-16 | Univ London Pharmacy | Ureylene derivatives |
| BRPI0810028A2 (pt) | 2007-04-17 | 2014-10-21 | Novartis Ag | Éteres de amidas de ácido naftaleno carboxílico no tratamento de câncer |
| FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| CN105367503A (zh) * | 2007-10-19 | 2016-03-02 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| AU2009244504A1 (en) * | 2008-05-05 | 2009-11-12 | Amgen Inc. | Urea compounds as gamma secretase modulators |
| FR2943669B1 (fr) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| CN101671301B (zh) * | 2009-05-05 | 2014-02-26 | 江苏省药物研究所有限公司 | 杂环取代的二苯脲类衍生物及其用途 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| DK2918588T3 (en) | 2010-05-20 | 2017-08-28 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
| FR2965262A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| FR2965263A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique |
| KR101762999B1 (ko) | 2011-04-18 | 2017-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료제 |
| ES2841809T3 (es) | 2011-06-03 | 2021-07-09 | Eisai R&D Man Co Ltd | Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
| WO2013048949A2 (en) * | 2011-09-26 | 2013-04-04 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| CN103508961B (zh) * | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| CA3022250A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| EP2937337A4 (en) | 2012-12-21 | 2016-06-22 | Eisai R&D Man Co Ltd | AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| KR102340654B1 (ko) | 2013-04-02 | 2021-12-16 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| JP6514703B2 (ja) | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
| MA40775A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | 抗がん剤 |
| EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| KR20180102544A (ko) | 2015-10-26 | 2018-09-17 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법 |
| NZ747135A (en) | 2016-04-04 | 2025-05-02 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| PL3439663T3 (pl) | 2016-04-04 | 2024-11-18 | Loxo Oncology, Inc. | Sposoby leczenia nowotworów wieku dziecięcego |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| RS61463B1 (sr) | 2016-05-18 | 2021-03-31 | Loxo Oncology Inc | Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP2020519576A (ja) | 2017-05-16 | 2020-07-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌の治療 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| AU2017444054B2 (en) * | 2017-12-21 | 2021-10-07 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Class of pyrimidine derivative kinase inhibitors |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594098B2 (en) * | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
| EP1616865A1 (en) * | 1997-12-22 | 2006-01-18 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| CN1308310C (zh) * | 2000-10-20 | 2007-04-04 | 卫材R&D管理有限公司 | 含氮芳环衍生物 |
| JP2005531488A (ja) * | 2001-10-09 | 2005-10-20 | ザ・ユニバーシティ・オブ・シンシナティ | 甲状腺癌を処置するためのｅｇｆ受容体阻害剤 |
| WO2003068228A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| AR037647A1 (es) * | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| DE602004011340T2 (de) * | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | Diaryl-harnstoffe mit kinasehemmender wirkung |
| US8637553B2 (en) * | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
-
2004
- 2004-11-26 RU RU2006122853/04A patent/RU2006122853A/ru unknown
- 2004-11-26 CA CA002546673A patent/CA2546673A1/en not_active Abandoned
- 2004-11-26 PE PE2004001167A patent/PE20051046A1/es not_active Application Discontinuation
- 2004-11-26 AR ARP040104414A patent/AR047496A1/es unknown
- 2004-11-26 EP EP04798101A patent/EP1689376A2/en not_active Withdrawn
- 2004-11-26 WO PCT/EP2004/013459 patent/WO2005051366A2/en active Application Filing
- 2004-11-26 US US10/580,259 patent/US20080312192A1/en not_active Abandoned
- 2004-11-26 BR BRPI0416935-2A patent/BRPI0416935A/pt not_active IP Right Cessation
- 2004-11-26 AU AU2004292773A patent/AU2004292773A1/en not_active Abandoned
- 2004-11-26 JP JP2006540401A patent/JP2007515400A/ja not_active Ceased
- 2004-11-26 KR KR1020067010328A patent/KR20060110307A/ko not_active Ceased
- 2004-11-26 TW TW093136547A patent/TW200529849A/zh unknown
-
2009
- 2009-07-30 AU AU2009203096A patent/AU2009203096A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060110307A (ko) | 2006-10-24 |
| AU2004292773A1 (en) | 2005-06-09 |
| TW200529849A (en) | 2005-09-16 |
| EP1689376A2 (en) | 2006-08-16 |
| PE20051046A1 (es) | 2006-01-11 |
| WO2005051366A3 (en) | 2007-12-21 |
| AR047496A1 (es) | 2006-01-25 |
| AU2009203096A1 (en) | 2009-08-20 |
| JP2007515400A (ja) | 2007-06-14 |
| CA2546673A1 (en) | 2005-06-09 |
| US20080312192A1 (en) | 2008-12-18 |
| BRPI0416935A (pt) | 2007-01-16 |
| WO2005051366A2 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| AU2019212478C1 (en) | Chemokine receptor modulators and uses thereof | |
| KR102800132B1 (ko) | Sting 작동 화합물 | |
| AU2017302635B2 (en) | Chemokine receptor modulators and uses thereof | |
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP2006507235A5 (ru) | ||
| RU2000127751A (ru) | Противоопухолевое средство | |
| TR200200234T2 (tr) | Tirozin Protein kinaz SYK purin türevleri inhibitörleri | |
| JP2008535902A5 (ru) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| US11084829B2 (en) | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | |
| CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
| RU2007124492A (ru) | Комбинации, включающие эпотилоны и ингибиторы протеинтирозинкиназы, и их фармацевтическое применение | |
| EP2685980B1 (en) | Methods and use of bifunctional enzyme-building clamp-shaped molecules | |
| ES2385850T3 (es) | Potenciador de radioterapia | |
| AU2014236370C1 (en) | 5-bromo-indirubins | |
| AU2023248361A1 (en) | Chemokine receptor modulators and uses thereof | |
| AU2006246204B2 (en) | Antineoplastic compounds and pharmaceutical compositions thereof | |
| RU2005105693A (ru) | Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний | |
| RU2006130865A (ru) | Производные пирролопиримидина, применяемые для лечения пролиферативных заболеваний | |
| US20120283280A1 (en) | Imidazotetrazinone-based combi-molecules | |
| EA200201154A1 (ru) | Бис(n,n'-бис(2-галоэтил)амино)фосфороамидаты в качестве противоопухолевых агентов | |
| EP4534543A1 (en) | Camptothecin prodrug and pharmaceutical composition thereof |